Get the Stockscreener App
114.54
0.13%
-0.15
After Hours:
114.60
0.06
+0.05%
Arcellx Inc stock is traded at $114.54, with a volume of 1.12M.
It is down -0.13% in the last 24 hours and up +0.69% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$114.69
Open:
$114.58
24h Volume:
1.12M
Relative Volume:
0.54
Market Cap:
$6.70B
Revenue:
$22.29M
Net Income/Loss:
$-228.93M
P/E Ratio:
-28.25
EPS:
-4.0547
Net Cash Flow:
$-212.59M
1W Performance:
+0.03%
1M Performance:
+0.69%
6M Performance:
+46.09%
1Y Performance:
+58.73%
1-Day Range:
$114.47
$114.70
1-Week Range:
$114.30
$114.91
52-Week Range:
$47.86
$114.91
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
114.54 | 6.71B | 22.29M | -228.93M | -212.59M | -4.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-22-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-16-25 | Initiated | Stifel | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition - Pharmaceutical Technology
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition - Benzinga
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - Stocktwits
Assessing Arcellx (ACLX) Valuation After Strong Multi Period Share Price Momentum - Yahoo Finance
Gilead to buy Ouro Medicines for up to $2.2 billion By Investing.com - Investing.com India
Gilead to buy Ouro Medicines for up to $2.2 billion - Investing.com
Gilead Sciences to Buy Arcellx in $7.8B Deal to Strengthen Cell Therapy Portfolio - The Healthcare Technology Report.
Trade Report: Can Arcellx Inc maintain its current growth rateRate Hike & Precise Entry and Exit Recommendations - baoquankhu1.vn
Arcellx earnings on deck ahead of Gilead acquisition close - Investing.com
Arcellx (NASDAQ:ACLX) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
Arcellx Inc stock hits all-time high at 114.82 USD By Investing.com - Investing.com South Africa
Arcellx (NASDAQ:ACLX) Sets New 52-Week HighHere's What Happened - MarketBeat
Arcellx Inc stock hits all-time high at 114.82 USD - Investing.com
Arcellx (ACLX) CFO gifts 5,000 shares to family foundation - Stock Titan
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders? - Finviz
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders? (2026-03-19) - Seeking Alpha
JPMorgan Chase & Co. Decreases Holdings in Arcellx, Inc. $ACLX - MarketBeat
M&A snapshot: Gilead acquires Arcellx for $7.8B - MSN
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - MSN
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
Gilead buys Arcellx to fast-track next-gen myeloma drug - MSN
Arcellx, Inc.Common Stock (NQ: ACLX - The Chronicle-Journal
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - AOL.com
Institution Moves: Is Arcellx Inc stock a smart retirement pickWeekly Trade Analysis & Risk Managed Investment Signals - baoquankhu1.vn
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth - MarketBeat
Arcellx and Aardvark Therapeutics Compared - National Today
(ACLX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders? - Finviz
Arcellx, Inc. $ACLX Position Lifted by HighVista Strategies LLC - MarketBeat
Bamco Inc. NY Increases Stake in Arcellx, Inc. - National Today
Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX - MarketBeat
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Arcellx set to report earnings amid $7.8B Gilead deal By Investing.com - Investing.com Nigeria
Integral Health Asset Management LLC Invests $12.32 Million in Arcellx, Inc. $ACLX - MarketBeat
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.ACLX - FinancialContent
Gilead Sciences to buy Arcellx in deal worth up to $7.8B - MSN
Shareholder Alert: The Ademi Firm Investigates Whether Arcellx Inc. Is Obtaining a Fair Price for Its Public Shareholders - 富途牛牛
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? - sharewise.com
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Declines By 38.0% - MarketBeat
User - The Chronicle-Journal
Arcellx shares surge after Gilead announces $7.8B takeover deal - MSN
Victory Capital Management Inc. Has $14.13 Million Stock Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Insider Monkey
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders? - Sahm
Arcellx set to report earnings amid $7.8B Gilead deal - Investing.com
American Century Companies Inc. Has $33.82 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead to buy US biotech Arcellx for up to $7.8 billion - MSN
ACLX Earnings History & Surprises | EPS & Revenue Results | ARCELLX INC (NASDAQ:ACLX) - ChartMill
Blue Owl Capital Holdings LP Buys Shares of 26,823 Arcellx, Inc. $ACLX - MarketBeat
Arcellx (NASDAQ: ACLX) — T. Rowe Price reports 4.5% holding in 13G/A - Stock Titan
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):